Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 231,318 shares, a drop of 93.2% from the July 15th total of 3,421,439 shares. Based on an average daily volume of 665,888 shares, the short-interest ratio is currently 0.3 days. Currently, 20.0% of the shares of the stock are sold short.

Calidi Biotherapeutics Price Performance

Calidi Biotherapeutics stock traded down $0.09 during trading hours on Thursday, hitting $1.54. 167,710 shares of the stock were exchanged, compared to its average volume of 229,426. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.92 and a current ratio of 1.92. The stock has a market capitalization of $1.86 million, a P/E ratio of -0.02 and a beta of 1.33. Calidi Biotherapeutics has a 12 month low of $1.48 and a 12 month high of $96.95. The business’s 50-day moving average is $2.17 and its two-hundred day moving average is $5.36.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its earnings results on Thursday, August 13th. The company reported ($2.94) EPS for the quarter.

Institutional Trading of Calidi Biotherapeutics

Several large investors have recently made changes to their positions in CLDI. DRW Securities LLC bought a new position in shares of Calidi Biotherapeutics in the fourth quarter valued at about $173,000. Geode Capital Management LLC lifted its position in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Calidi Biotherapeutics during the 4th quarter worth about $25,000. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.